Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
In the latest study, researchers found the main genetic mutations in renal cell cancer, possibly by using artificial intelligence (AI). The scientists injected mRNA vaccine made against proteins ...
VAX-31’s safety, tolerability, and immunogenicity are being assessed in this trial on healthy infants. Vaxcyte anticipat ...
The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their ...
SAN CARLOS, Calif. - Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company valued at $10.78 billion, has announced the commencement of the final stage of its Phase 2 study for VAX-31, a ...
Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerabi ...
The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...
What you need to know ### BMJ Learning To obtain accredited continuous professional development points, subscribers to BMJ Learning can complete the full module at The module contains seven ...
Researchers found that 22,209 of 161,187 children had an invalid vaccine dose. HealthDay News — Overall, 15.4 percent of children aged 0 to 35 months receive an invalid vaccine dose, receiving a ...
The frequency of serotypes was also analyzed according to the coverage of all the pneumococcal conjugate vaccines approved (10, 13, 15, and 20-valent). All data preprocessing and analyses were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback